Skip to main content

Table 4 Multivariable regression odds ratios for chemotherapy recommendation following ODX testing

From: Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016

Variable Odds Ratio (95% CI) P-Value
Year of Diagnosis
 2010 Ref Ref
 2011 0.87 (0.48–1.60) 0.66
 2012 0.65 (0.34–1.24) 0.18
 2013 0.73 (0.39–1.36) 0.31
 2014 0.66 (0.36–1.19) 0.16
 2015 0.44 (0.24–0.82) < 0.01**
 2016 0.51 (0.27–0.96) 0.04*
Patient Age at Diagnosis (Years)
 < 50 Ref Ref
 50–59 0.73 (0.48–1.10) 0.13
 60–69 0.39 (0.25–0.61) < 0.01**
 > 69 0.35 (0.18–0.66) < 0.01**
Grade
 I Ref Ref
 II 1.73 (1.16–2.59) < 0.01**
 III/IV 3.55 (2.17–5.83) < 0.01**
 Unknown 2.61 (0.34–20.30) 0.35
LN Status
 Negative Ref Ref
 Positive 3.54 (2.29–5.46) < 0.01**
 Unknown 1.26 (0.39–4.08) 0.69
Tumor Size (mm)
 0.1–19 Ref Ref
 20–39 1.51 (0.94–2.45) 0.08
 > 40 4.36 (1.98–9.62) < 0.01**
 Unknown 1.03 (0.18–6.05) 0.98
Clinical Stage
 1 Ref Ref
 2 1.50 (0.90–2.50) 0.11
 3 / 4 2.72 (0.86–8.65) 0.08
MD Clinical Experience (Years)
 < 10 Ref Ref
 10–19 1.89 (0.74–4.81) 0.17
 20–29 4.05 (1.57–10.43) < 0.01**
 > 29 4.48 (1.68–11.95) < 0.01**
MD Gender
 Female Ref Ref
 Male 0.50 (0.34–0.74) < 0.01**
Patient Volume 1.01 (1.01–1.03) 0.04*
Average Patient Age
 < 65 Years Ref Ref
 > 65 Years 0.72 (0.34–1.56) 0.40
ODX RS Classification
 Low Ref Ref
 Intermediate 12.30 (8.70–17.38) < 0.01**
 High 233.08 (95.40–569.42) < 0.01**
  1. * significant at the 0.05 level
  2. ** significant at the 0.01 level